Is transcatheter aortic valve implantation (TAVI) indicated for patients with severe aortic regurgitation (AR) who are high or prohibitive surgical risk?

TAVI in Aortic Regurgitation

TAVI should not be performed in patients with isolated severe native aortic regurgitation who are candidates for surgical aortic valve replacement, but may be considered in highly selected inoperable patients at experienced centers using purpose-built devices. 1

Current Guideline Recommendations

Standard-of-Care Position

The 2020 ACC/AHA guidelines explicitly state that TAVI should not be performed (Class III: Harm) in patients with isolated severe AR who have indications for surgical AVR and are surgical candidates. 1 This represents the strongest evidence-based recommendation against routine TAVI use in native AR.

The 2012 ACC/AHA/SCAI/STS expert consensus document reinforces this position, noting that TAVI is not currently recommended in patients with severe AR because of limited available information. 1 The document emphasizes that additional scientific data must be collected to ascertain the risk/benefit ratio prior to integration into routine clinical care. 1

Why TAVI Fails in Native AR

The fundamental problem is anatomical: devices optimized for calcific aortic stenosis encounter technical obstacles in native AR, including large non-calcified annuli, elliptical root geometry, and high stroke volumes, leading to suboptimal anchoring, residual paravalvular regurgitation, and device embolization. 2

Bicuspid aortic valve morphology—a common cause of AR—is considered a contraindication because of the risk of incomplete prosthesis expansion. 3

The Narrow Exception: Inoperable High-Risk Patients

When to Consider TAVI for AR

TAVI may be considered in experienced centers for selected patients ineligible for surgical AVR. 1 This applies only when:

• Prohibitive surgical risk is present, defined as an estimated ≥50% risk of mortality or irreversible morbidity at 30 days (as assessed by one cardiologist and two cardiothoracic surgeons), or other factors such as frailty, prior radiation therapy, porcelain aorta, and severe hepatic or pulmonary disease. 1
• Predicted survival exceeds 12 months with reasonable expectation of quality-of-life improvement. 1
• Suitable aortic and vascular anatomy is confirmed, including both aortic annulus size appropriate for available devices and adequate vascular access. 1

Device Selection Matters

Purpose-built AR systems with leaflet-engaging anchoring and enhanced sealing have shown encouraging outcomes in feasibility and pivotal studies. 2 The ALIGN-AR trial using the Trilogy transcatheter heart valve (a dedicated AR device) demonstrated:

• Technical success in 95% of patients 4
• 30-day mortality of 2% 4
• 1-year mortality of 7.8%, meeting non-inferiority compared to historical surgical controls 4
• Permanent pacemaker requirement in 24% of patients 4

In contrast, off-label use of conventional TAVI devices designed for stenosis yields suboptimal results. A 2013 registry of CoreValve use in native AR showed that 18.6% of patients required a second valve during the index procedure for residual regurgitation, and this occurred exclusively in patients without valvular calcification (p=0.014). 5

Practical Algorithm for Decision-Making

Step 1: Confirm Surgical Candidacy

• Calculate STS-PROM and EuroSCORE II 1
• Assess for prohibitive-risk features: frailty indices, porcelain aorta, prior chest radiation, severe organ dysfunction 1
• If surgical risk is acceptable → proceed to surgical AVR 1

Step 2: Evaluate Anatomical Suitability (If Inoperable)

• Measure aortic annulus dimensions: must be 18–25 mm for balloon-expandable or 20–27 mm for self-expandable devices 3
• Assess valve morphology: exclude bicuspid valves 3
• Evaluate calcification pattern: asymmetric heavy calcification that could compress coronary ostia is a contraindication 3
• Confirm absence of left ventricular apical thrombus 3

Step 3: Assess Vascular Access

• Transfemoral route requires iliac/femoral arteries ≥6–9 mm diameter (device-dependent) with acceptable calcification and tortuosity 3
• Severe pulmonary hypertension contraindicates transapical approach but permits transfemoral access 6

Step 4: Heart Team Evaluation

• Multidisciplinary assessment by interventional cardiologists, cardiac surgeons, imaging specialists, and anesthesiologists is mandatory 1, 7
• Confirm life expectancy >1 year and anticipated quality-of-life benefit 1, 7

Step 5: Device Selection

• Prioritize purpose-built AR devices (e.g., Trilogy/JenaValve) over conventional TAVI valves when available 4, 2
• If using conventional devices, presence of at least moderate valvular calcification improves anchoring and reduces need for second valve 5

Critical Pitfalls to Avoid

Do not attempt TAVI in AR patients who are acceptable surgical candidates—the guideline recommendation is Class III (harm). 1 This is non-negotiable.

Do not use conventional TAVI devices in non-calcified AR—the 2013 registry showed that all patients requiring second valves had absent calcification (p=0.014). 5

Do not proceed without comprehensive CT angiography—accurate annular sizing is critical to minimize paravalvular leak and device migration. 3, 7

Recognize that even with dedicated devices, paravalvular regurgitation remains a concern—the ALIGN-AR trial reported mild PVL in 22.2% at 30 days. 4

Emerging Evidence vs. Current Guidelines

While recent research shows promise for dedicated AR devices 4, 8, 9, current guidelines have not yet incorporated these findings into formal recommendations. The 2020 ACC/AHA guideline predates the ALIGN-AR trial results and maintains a Class III recommendation against TAVI in native AR. 1

Until guidelines are updated, TAVI for native AR should be restricted to clinical trials or compassionate use in truly inoperable patients at high-volume centers with structural heart disease expertise. 1, 2